We are an immuno-oncology company specializing in cancer therapeutics.
We have a comprehensive intellectual property portfolio for treatment of solid tumors to improve patient outcomes.
Learn More GlyTherix
Therapeutic & Imaging Applications Miltuximab® Our patented antibodies target GPC-1, a protein over expressed in prostate, pancreatic, bladder, esophageal and other solid tumors.
We have completed a first in human trial using our antibody, called Miltuximab®.
Learn More Our patented antibodies target GPC-1, a protein over expressed in prostate, pancreatic, bladder, esophageal and other solid tumors
We have completed a first in human trial using our antibody, called Miltuximab
News More Find out about the vital work we do
developing solid tumors therapeutics.

Miltuximab® for Therapeutic & Imaging Applications.

Our patented antibodies target Glypican-1 (GPC-1), a protein overexpressed in prostate, pancreatic, bladder, esophageal and other solid tumors. We are examining multiple mechanisms of action including:
  • Radio immunotherapy
  • Bispecific antibodies
  • Immune cell engagement and activation
We have now completed a first in-human trial using Miltuximab®, our anti-GPC-1 monoclonal antibody (ANZCTR registry). The trial dosed 12 patients and no drug-related adverse events were observed. Glytuzumab® refers to the humanized version of Miltuximab® and also targets human GPC-1. The Glytuzumab® program is currently undergoing Lead Optimisation and Lead Selection stages. Several humanized leads have been generated with similar binding affinities as that of the parent molecule Miltuximab®. The final Glytuzumab® lead selected will be taken forward from cell line development through to large scale GMP production for future clinical trials.

Achievements

N

2019

First-In-Human Clinical trial of Miltuximab® conjugated to 67Gallium for imaging met primary endpoint of safety in all patients

Preclinical work now completed for upcoming Phase I Clinical trial in GPC-1 expressing solid tumours. This will use Miltuximab® labelled with either 89Zirconium for imaging or 177Lutetium for therapy

Antibody composition of matter patents granted EU and US

N

2018

Completion of accrual for clinical study of Miltuximab® in prostate, bladder and pancreatic cancers

N

2017

The second stage of pioneering MILGa clinical trial of Miltuximab®

N

2016

Commenced First-In-Human trial of Miltuximab® 

2015 Eureka Prize

Excellence in Interdisciplinary Scientific Research

Major Australian prize for innovation awarded to our CEO, Brad Walsh, and university collaborators.

Find Out More Information

  • About our groundbreaking first-in-human trial of our novel cancer target >More
  • About how your company and Glytherix could partner to deliver better cancer therapeutics >More 

9 + 14 =

Address Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia Phone International +612 9850 4000 In Australia 02 9850 4000 Compare your time zone with Sydney here Email info@glytherix.com
Finding Us We are based in Sydney, adjacent to one of Australia’s leading universities, Macquarie University, and the Macquarie University Hospital, one of our key collaborators.

Headquarters of Glytherix

Privacy Policy